Skip to content

Categories: biotech company

  • Biotech founded by ex-Novo reseacher raises capital for new oral obesity treatment

    The biotech company, Pila Pharma, is raising 20 million Swedish kronor in an almost fully covered capital raise, which includes a stock option for future use. The goal is to expand the clinical pipeline with a separate dedicated obesity track and thereby explore more applications for the company's oral TRPV1 inhibitor for obesity and type 2 diabetes, a potential first-in-class candidate.

    Biotech founded by ex-Novo reseacher raises capital for new oral obesity treatment. Photo: Pila Pharma.
  • Hunt for Next Obesity Breakthrough Sends Biotech Stock Soaring

    Investors worldwide are scouring for their next big win after the door to the extremely lucrative obesity market was opened by pharmaceutical giants Novo Nordisk and Eli Lilly. Now benefiting on the Swedish stock exchange is a smaller Nordic biotech company.